Search company, investor...

Celgen Biopharmaceuticals


Unattributed VC | Alive

About Celgen Biopharmaceuticals

Shanghai Celgen Biopharmaceutical is a bio-similar biopharmaceuticals drugs developer and manufacture in China mainly focused on Inflammation, Oncology and Metabolic Disease. Celgen's main product is a Monoclonal Antibody (MAB) called Etanercept a Generic version of Amgen's Enbrel used for the treatment of inflammatory conditions such as Rheumatoid arthritis, Juvenile rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasis.

Headquarters Location

Shanghai, Shanghai,


Missing: Celgen Biopharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Celgen Biopharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Celgen Biopharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Celgen Biopharmaceuticals is included in 1 Expert Collection, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Celgen Biopharmaceuticals Frequently Asked Questions (FAQ)

  • Where is Celgen Biopharmaceuticals's headquarters?

    Celgen Biopharmaceuticals's headquarters is located at Shanghai.

  • What is Celgen Biopharmaceuticals's latest funding round?

    Celgen Biopharmaceuticals's latest funding round is Unattributed VC.

  • Who are the investors of Celgen Biopharmaceuticals?

    Investors of Celgen Biopharmaceuticals include China-Israel Value Capital.

  • Who are Celgen Biopharmaceuticals's competitors?

    Competitors of Celgen Biopharmaceuticals include Philogen, PhaseBio Pharmaceuticals, Viventia, Kythera Biopharmaceuticals, Bioceros and 12 more.

Compare Celgen Biopharmaceuticals to Competitors


Glycotope is a biopharmaceutical company in glycomics and its application for development of biopharmaceuticals.

Sarossa Capital

Sarossa, formerly Antisoma, is an investment holding and management company whose principal activity is investment in and growth and development of businesses which present opportunities for value creation.

Aphios Logo

Biopharmaceutical company developing enabling technology platforms and enhanced natural therapeutics for certain infectious diseases, cancers and CNS disorders. Ehanced therapeutics include small molecules from medicinal plants and marine organisms, and improved drug delivery formulations of protein macromolecules and hydrophobic anticancer drugs.


ugichem is developing antisense drugs based on its proprietary Ugimer platform for unmet medical needs in immune-mediated inflammatory diseases (IMID). Ugimers overcome the shortcomings of standard antisense technologies or RNAi. In contrast, Ugimers are not derived from natural nucleic acids but are based on the peptide nucleic acid (PNA) backbone and carry specific side chains for improved delivery, efficacy and specificity. This innovative design provides Ugimers with unique biopharmaceutical properties allowing them access to previously inaccessible organs, cells and cellular compartments, including the immune system. Moreover, Ugimers are the first and only antisense drugs that have efficacy in mitochondria.


Sanomune is a private biotech start-up focused on neurological and autoimmune diseases. The company's technology is based on the repurposing of a safe, oral biological to treat large market indications. Sanomune's lead product, SAN-61, is a potential first-in-class treatment targeting the dual hallmark pathologies of Alzheimer's (AD): amyloid beta plaque deposition and the formation of neurofibrillary tangles. No other known therapy can effectively target both aspects of the disease. Sanomune's pipeline also includes products for rheumatoid arthritis (RA) multiple sclerosis (MS), stroke and diabetes. One patent has issued and six others have been filed. Sanomune is developing a recombinant form of its core biological as well as a nasal delivery device. With a $1.1 million Series A financing, Sanomune has secured compelling efficacy data, a strong IP position and has submitted, just recently, for regulatory approval to begin Phase II trials for AD and RA.

Affectis Pharmaceuticals

Affectis Pharmaceuticals, fka neuronova, is a biopharmaceutical company developing drugs for the treatment of psychiatric and inflammatory disorders.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.